Toth Financial Advisory’s ImmunityBio IBRX Stock Holding History

Toth Financial Advisory’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.23K	Hold	140	–	–	﹤0.01%	805
2026 Q1	$1.07K	Buy	+140	New	+$958	﹤0.01%	804
2024 Q3	–	Sell	-150	Closed	-$948	–	733
2024 Q2	$948	Buy	+150	New	+$989	﹤0.01%	700

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Toth Financial Advisory's IBRX Position: Q2 2026 in Review

Toth Financial Advisory held its ImmunityBio (IBRX) position steady in Q2 2026 at 140 shares worth $1.23K. The position accounts for ﹤0.01% of the portfolio, ranked #805.

Toth Financial Advisory first reported a position in IBRX in Q2 2024 and has held it in 3 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Toth Financial Advisory held 140 shares of ImmunityBio worth $1.23K as of Q2 2026.
Toth Financial Advisory left its ImmunityBio share count unchanged in Q2 2026.
ImmunityBio made up ﹤0.01% of Toth Financial Advisory's portfolio in Q2 2026, its #805 holding.
Toth Financial Advisory first reported a position in ImmunityBio in Q2 2024 and has held it in 3 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Toth Financial Advisory's 13F filing for Q2 2026, filed 14 Jul 2026.